Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastric NET”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03220217
What this trial is testing

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Who this might be right for
Gastro-Enteropancreatic Neuroendocrine Tumor
Ipsen 29
Large-scale testing (Phase 3)Active Not RecruitingNCT00569127
What this trial is testing

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Who this might be right for
Colorectal Neuroendocrine Tumor G1Gastric Neuroendocrine Tumor G1Neuroendocrine Neoplasm+2 more
National Cancer Institute (NCI) 427
Very early researchUnknownNCT05359146
What this trial is testing

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

Who this might be right for
Neuroendocrine Neoplasia's (NENs)Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
University Hospital, Basel, Switzerland 16
Not applicableNot Yet RecruitingNCT07014254
What this trial is testing

Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies

Who this might be right for
Pancreatic Ductal Adenocarcinoma (PDAC)Adenocarcinoma of the StomachColorectal Cancer Metastatic+1 more
Xijing Hospital 20
Testing effectiveness (Phase 2)Ended earlyNCT02078843
What this trial is testing

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Insel Gruppe AG, University Hospital Bern 54
Testing effectiveness (Phase 2)Looking for participantsNCT06943521
What this trial is testing

MT-4561 in Patients With Various Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal Cancer+13 more
Tanabe Pharma America, Inc. 27
Large-scale testing (Phase 3)Active Not RecruitingNCT05050942
What this trial is testing

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Camurus AB 332
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more
Perspective Therapeutics 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600233
What this trial is testing

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsPancreatic Neuroendocrine TumorGastro-enteropancreatic Neuroendocrine Tumor+2 more
TaiRx, Inc. 34
Testing effectiveness (Phase 2)Study completedNCT05199584
What this trial is testing

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Who this might be right for
Solid Tumors With PTCH1 Loss-of-function Mutations
Endeavor Biomedicines, Inc. 20
Not applicableUnknownNCT04294589
What this trial is testing

Evaluation of NETs in Patients With Solid Cancers Associated With a High Risk of Venous Thromboembolic Events

Who this might be right for
Pancreatic CancerGastric CancerColorectal Cancer
Assistance Publique - Hôpitaux de Paris 250
Not applicableLooking for participantsNCT07635316
What this trial is testing

Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 4,023
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Not applicableLooking for participantsNCT06356467
What this trial is testing

Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs

Who this might be right for
Neuroendocrine TumorsGEP-NET
IRCCS San Raffaele 450
Large-scale testing (Phase 3)Active Not RecruitingNCT03972488
What this trial is testing

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Who this might be right for
Gastro-enteropancreatic Neuroendocrine Tumor
Advanced Accelerator Applications 226
Early research (Phase 1)Looking for participantsNCT06441331
What this trial is testing

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Who this might be right for
Somatostatin Receptor PositiveNETsLymphoma+5 more
ITM Solucin GmbH 20
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Testing effectiveness (Phase 2)Ended earlyNCT05987176
What this trial is testing

Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases

Who this might be right for
Neuroendocrine Tumor G1 (NET G1)/CarcinoidNeuroendocrine Tumor Grade 2Neuroendocrine Tumors+3 more
Imperial College London 1
Not applicableLooking for participantsNCT04949282
What this trial is testing

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Who this might be right for
Neuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Next Page